Technological support in clinical trials
Company profile

The goal of InSilicoTrials Technologies is to fuel innovations in healthcare by creating a collaborative platform that facilitates the technology transfer of modeling and simulations (M&S) tools from the scientific community to biomedical and pharmacological companies, encouraging developers and models’ creators to capitalize on their work and enabling widespread exploitation of highly advanced in silico solutions.

Launched in 2016, is the world’s first cloud platform that enables healthcare companies and institutions to integrate the most advanced M&S tools into their research and development (R&S) processes., allowing to accelerate time and reduce costs needed to develop new medical devices and pharmacological products.

InSilicoTrials Technologies harbors a diverse and balanced team with extensive expertise and know-how on medical product and pharma R&D, biomedical and biomechanical M&S, healthcare regulations and IT development.



Main products / services

The first medical devices application hosted on the platform is NuMRis, implemented in collaboration with the U.S. F.D.A. Center for Devices and Radiological Health, and ANSYS, Inc. for the assessment of MRI radiofrequency (RF) safety for medical implants.

The first pharma application hosted on the platform is QT/TdP Risk Screen, a user-friendly tool implemented in collaboration with Universitat Politècnica de València and Fundació Institut Mar D’Investigacions Mèdiques, that enables a highly accurate classification of drug compounds, paving the way to a potential break-through in in silico proarrhythmic risk assessment.

In 2018 InSilicoTrials Technologies acquired CONSELF, leader platform for engineering simulations solutions in the cloud, with over 3000 users in the previous 3 years, to address the increasing need of in silico mechanical testing for traditional and 3d-printed medical devices.


Partnerships and collaborations

Building upon a strong base of research and industrial collaborations, InSilicoTrials Technologies aims to democratize the use of computational models and simulations in the healthcare world to accelerate and improve their innovative processes.

Our vision leverages strong strategic synergy with regulators (U.S. Food and Drug Administration, European Medicine Agency), market leader industrial partners (e.g. Microsoft Azure and ANSYS) and scientific collaborators (including Erasmus University Medical Center, Emory University Hospital, University of California Los Angeles, Université Libre de Bruxelles and Fraunhofer-Gesellschaft).

InSilicoTrials Technologies is member of the Avicenna Alliance, Pistoia Alliance and CompBiomed Centre of Excellence.


Address: via Flavia 23/1 c/o BIC Incubatori FVG Trieste
Mail: Luca Emili